1. Home
  2. XRX vs EDIT Comparison

XRX vs EDIT Comparison

Compare XRX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xerox Holdings Corporation

XRX

Xerox Holdings Corporation

HOLD

Current Price

$0.93

Market Cap

416.3M

Sector

Technology

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$1.86

Market Cap

422.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XRX
EDIT
Founded
1906
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
416.3M
422.3M
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
XRX
EDIT
Price
$0.93
$1.86
Analyst Decision
Hold
Buy
Analyst Count
4
13
Target Price
$1.75
★ $6.10
AVG Volume (30 Days)
★ 9.4M
2.2M
Earning Date
10-29-2026
11-09-2026
Dividend Yield
★ 10.94%
N/A
EPS Growth
23.26
★ 37.50
EPS
N/A
★ N/A
Revenue
★ $117,000,000.00
$31,937,000.00
Revenue This Year
$8.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 132.64
52 Week Low
$0.88
$1.66
52 Week High
$3.78
$3.94

Technical Indicators

Market Signals
Indicator
XRX
EDIT
Relative Strength Index (RSI) 19.20 32.14
Support Level N/A $1.82
Resistance Level $1.92 $3.00
Average True Range (ATR) 0.16 0.22
MACD -0.02 -0.08
Stochastic Oscillator 2.70 0.42

Price Performance

Historical Comparison
XRX
EDIT

About XRX Xerox Holdings Corporation

Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: